Ophthalmic Pilocarpine Brimonidine Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for presbyopia lack effective topical solutions that are stable, safe, and tolerable, with existing formulations facing challenges in achieving a balance for the delicate mammalian eye, leading to issues with safety, efficacy, and stability.
Innovation Solution
Development of ophthalmic compositions comprising pilocarpine and brimonidine compounds with specific tonicity characteristics, including low pH and reduced saccharide content, using quaternary ammonium salts and penetration enhancers like polysorbate 80 to enhance stability and reduce irritation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing ophthalmic formulations are used, then treatment options are available, but stability, safety, and tolerability are compromised due to inability to achieve proper balance for the delicate mammalian eye
Solution Approach 1:
The patent applies parameter changes by optimizing the pH to be less than 7.0 (preferably less than 6.5, more preferably less than 6.0), controlling tonicity to be less than 0.9% NaCl equivalent, and adjusting excipient concentrations. These parameter modifications create a formulation environment that enhances drug stability while reducing ocular irritation and improving tolerability.
Solution Approach 2:
The patent employs composite materials by combining pilocarpine and brimonidine in a fixed-dose ophthalmic formulation with specific excipients including buffers, tonicity agents, and preservatives. This composite approach allows the formulation to simultaneously achieve multiple objectives: maintaining drug stability, ensuring safety, and improving tolerability through synergistic interactions among components.
2Reliability
If pilocarpine and brimonidine are combined in ophthalmic formulations, then treatment efficacy for presbyopia is improved, but formulation stability and reduced irritation are compromised
Solution Approach 1:
The patent utilizes parameter changes by establishing specific pH ranges (less than 7.0, preferably less than 6.5) and tonicity levels (less than 0.9% NaCl equivalent) that simultaneously maintain the stability of both pilocarpine and brimonidine compounds while preserving their therapeutic efficacy for presbyopia treatment.
Solution Approach 2:
The patent employs intermediary substances including buffers, tonicity agents, and preservatives that mediate between the active pharmaceutical ingredients and the ocular environment. These intermediaries protect the drug compounds from degradation while maintaining formulation stability and reducing irritation during presbyopia treatment.
3Ease of operation
If conventional ophthalmic formulations are used, then administration is simple, but side effects and irritation are increased
Solution Approach 1:
The patent applies parameter changes by optimizing pH (less than 7.0), tonicity (less than 0.9% NaCl equivalent), and excipient concentrations to reduce ocular irritation and side effects. These modifications maintain ease of administration as simple eye drops while significantly improving patient comfort and tolerability.
Solution Approach 2:
The patent converts potentially harmful high pH and high tonicity conditions into beneficial low pH and low tonicity parameters. This transformation reduces ocular irritation and side effects while maintaining formulation stability and therapeutic efficacy, turning what would be formulation challenges into advantages for patient comfort.
Data Source
AI summary
The present invention provides stable, pharmaceutically acceptable and ophthalmologically suitable compositions comprising therapeutically effective amounts of both a pilocarpine compound and a brimonidine compound for treating an ocular condition, the compositions comprising a low amount of sodium chloride present in a limited ratio with the active pharmaceutical ingredient(s). In certain embodiments, provided compositions are free of both a borate buffer and a citrate buffer. Compositions provided by the invention surprisingly demonstrate pharmaceutically acceptable stability characteristics when stored under controlled room temperature conditions for an extended period of time. Further, the invention provides methods of manufacturing such compositions in both liquid (solution) and gel form, and methods of their use in treating ocular conditions, such as presbyopia.